Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.
RemeGen Co., Ltd. recently held its 2025 third extraordinary general meeting (EGM) where key resolutions were passed. The meeting saw a significant turnout with 47.58% of shares represented. Key resolutions included the approval of expected day-to-day related party transactions for 2026 to 2028 and amendments to several governance policies. These decisions are poised to influence the company’s operational strategies and governance structure, potentially impacting its market position and stakeholder relations.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$88.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on the development and commercialization of innovative biologics for the treatment of cancer, autoimmune, and other serious diseases.
Average Trading Volume: 6,242,775
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.24B
For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.